Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU

Shots:

  • Calliditas to receive $24M upfront and is eligible to receive ~$91M as regulatory and commercialization milestones along with royalties on net sales
  • The companies collaborated to develop a new oral formulation that downregulates IgA1 by combining Calliditas’ drug-delivery expertise with STADA’s extensive marketing and sales platform for specialty and nephrology therapies
  • The companies collaborated to bring a specialty therapy for IgAN in EU market, If approved, the therapy would be available to EU patients in H1’22 & would be the first approved treatment in the EU for chronic autoimmune kidney disease IgAN

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Pharmaceutical Technology

The post Calliditas Signs a License Agreement with STADA to Commercialize Specialty Therapy for the Treatment of IgA Nephropathy in EU first appeared on PharmaShots.